158461-29-1

Basic information

• Product Name: tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate
• Synonyms: tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate
• CAS NO: 158461-29-1
• Molecular Weight: 268.269
• Mol File: 158461-29-1.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate(158461-29-1)
• EPA Substance Registry System: tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate(158461-29-1)

Safety Data

• Hazardous Substances Data: 158461-29-1(Hazardous Substances Data)

Upstream product

• 60144-52-7 tert-butyl 3-methoxyphenylcarbamate 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 90321-73-6 3-methoxy-2-nitrobenzoyl azide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 16554-47-5 3-methoxy-2-nitroaniline 
• 4129-17-3 diphenylphosphoranyl azide 
• 15865-57-3 2-nitro-3-methoxybenzoyl chloride 

Downstream Products

• 33604-87-4 2-chloro-4-methoxy-1-methyl-1H-benzimidazole 
• 177477-60-0 3-methoxy-N₁-methylbenzene-1,2-diamine 
• 1143575-95-4 (3-methoxy-2-nitrophenyl)-(methyl)amine 
• 1143575-94-3 tert-butyl (3-methoxy-2-nitrophenyl)-(methyl)carbamate 
• 158461-77-9 {1-Methyl-2-[2-pyridin-2-yl-6-(2,2,2-trifluoro-ethoxy)-phenylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 158461-90-6 {1-Methyl-2-[2-pyridin-3-yl-6-(2,2,2-trifluoro-ethoxy)-phenylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 158461-73-5 [2-(2-Methoxy-6-pyridin-2-yl-phenylcarbamoyl)-1-methyl-ethyl]-carbamic acid tert-butyl ester 
• 158461-37-1 2-[2-Nitro-3-(2,2,2-trifluoro-ethoxy)-phenyl]-pyridine 
• 158461-38-2 3-[2-Nitro-3-(2,2,2-trifluoro-ethoxy)-phenyl]-pyridine 
• 158461-61-1 2-Pyridin-3-yl-6-(2,2,2-trifluoro-ethoxy)-phenylamine 
• 158461-51-9 2-Pyridin-2-yl-6-(2,2,2-trifluoro-ethoxy)-phenylamine 
• 158461-33-7 3-(3-Methoxy-2-nitro-phenyl)-pyridine 
• 158461-32-6 2-(3-methoxy-2-nitrophenyl)pyridine 
• 159958-45-9 2-(3-hydroxy-2-nitrophenyl)pyridine 

Relevant articles and documents

Visible-Light-Mediated Nitration of Protected Anilines

The photocatalytic nitration of protected anilines proceeds with riboflavin tetraacetate as an organic photoredox catalyst. Sodium nitrite serves as the NO2 source in this visible-light-driven room temperature reaction. Various nitroanilines are obtained in moderate to good yields without the addition of acid or stoichiometric oxidation agents. The catalytic cycle is closed by aerial oxygen as the terminal oxidant.

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2- (trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin- 5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.